Aug 19 (Reuters) - CSL Ltd, Australia’s biggest biotech firm, on Wednesday reported a 17% rise in annual profit, boosted by strong demand for immunoglobulin drugs and other products.
The maker of treatments for blood-related diseases and influenza vaccines posted a underlying net profit after tax at constant currency of $2.25 billion for the year ended June 30, compared with $1.92 billion a year ago.
CSL, which in May entered the race to produce a treatment for COVID-19, declared a final dividend of $1.07 per share, up from $1 per share a year earlier. (Reporting by Shashwat Awasthi and Shruti Sonal in Bengaluru; Editing by Shinjini Ganguli)
Our Standards: The Thomson Reuters Trust Principles.